SequelSEC

Apogee Therapeutics, Inc. APGE

Biological Products, (No Diagnostic Substances) · CIK 0001974640 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$285.60M
Fiscal year ended 2025-12-31
Free cash flow
-$232.60M
Fiscal year ended 2025-12-31

Apogee Therapeutics, Inc. (APGE) reported net income of -$255.84M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Apogee Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Apogee Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$285.60M-$216.87M-$93.00M
Net income-$255.84M-$182.15M-$83.98M
Research & development$214.71M$167.86M$68.42M
Weighted-average diluted sharesshares 60.69Mshares 55.19Mshares 25.01M
Pretax income-$255.56M-$182.13M-$83.98M
Income tax expense$278.00K$18.00K$0
Diluted EPS$-4.22$-3.30$-3.36
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$70.88M$49.00M$24.58M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Apogee Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$131.55M$141.79M$118.32M
Total assets$937.13M$753.95M$401.40M
Current assets$741.36M$529.71M$398.41M
Total liabilities$33.25M$37.16M$21.49M
Current liabilities$27.91M$28.56M$20.56M
Total equity incl. NCIUnavailableUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.22M$1.07M$2.14M

Cash flow

Apogee Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$227.45M-$171.17M-$74.76M
Capital expenditures$5.15M$1.15M$167.00K
Investing cash flow-$179.57M-$300.46M-$273.91M
Financing cash flow$396.49M$495.11M$315.39M
Net change in cash-$10.53M$23.47M-$33.28M
Stock-based compensation$46.28M$23.33M$6.10M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Apogee Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$232.60M-$172.33M-$74.93M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio26.57x18.55x19.38x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open APGE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-02View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.